BERGEN, Norway--(BUSINESS WIRE)--BerGenBio has secured NOK7 million from local Sarsia Seed and Development funds to continue its leading research and development activities into new and original cancer treatments. The company’s CellSelect™ advanced technology platform is gaining increasing traction amongst drug developers internationally because of its ability to help them understand more fully the underlying causes of cancer and in turn develop completely new paradigms for its treatment. In addition to private equity, BerGenBio has also been awarded grants from Innovation Norway and FORNY. The company has recently received additional financial support from the NFR to enable its life sciences graduate recruits to continue PhD studies.
